Loading
Latest filing published 08 Jul 2024 for Tempest Therapeutics, Inc., €68k. Read the official filing
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Stephen R. Brady is a declared insider at 2 companies; the most frequent names are Immune Design Corp. and Tempest Therapeutics, Inc. The record holds 2 filings, for trades running from 4 January 2016 to 3 July 2024.
On the market, this insider has only ever bought: 1 purchase, €68k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant. In 2024 alone, the filings show 1 purchase and no sales.
The record was last updated on 8 July 2024 with an open-market purchase (€68k) in Tempest Therapeutics, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations